Related Experiment Videos
Assuming the worst may not be bad at all. Carvedilol in heart failure treatment
B M Schmidt1, C P Janson, M Wehling
1Institute for Clinical Pharmacology, Faculty of Clinical Medicine at Mannheim, Ruprecht Karls University Heidelberg.
Insights
Carvedilol significantly reduces mortality in patients with chronic heart failure (CHF). This meta-analysis confirms its benefit, even under worst-case analysis scenarios for carvedilol treatment.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Trials
Background:
- Carvedilol, a beta- and alpha(1)-adrenoceptor blocker, improves left ventricular function in chronic heart failure (CHF).
- The impact of carvedilol on mortality in CHF patients remains a subject of debate.
- Existing data from large-scale studies require comprehensive meta-analysis to clarify mortality benefits.
Purpose of the Study:
- To conduct a meta-analysis of mortality data from two major carvedilol heart failure study programs.
- To evaluate the effect of additional carvedilol treatment on mortality in patients with CHF on standard therapy.
- To analyze the study designs and limitations of the included trials.
Main Methods:
- A meta-analysis was performed on mortality data from the US Carvedilol Heart Failure Study and the Australia/New Zealand Heart Failure Research Collaborative Group study.
- A 'worst-case analysis' was employed, assigning all deaths and withdrawals during the run-in phase to the carvedilol group.
- The random effects model was used to calculate the relative risk of death.
Main Results:
- The meta-analysis revealed a significantly reduced relative risk of death by 0.55 (95% CI: 0.325-0.924, p < 0.05) in patients treated with carvedilol compared to standard treatment alone.
- This significant reduction in mortality was observed even when applying the stringent 'worst-case analysis' methodology.
Conclusions:
- Carvedilol treatment significantly reduces mortality in patients diagnosed with chronic heart failure.
- The observed mortality benefit is robust, persisting even under conservative analytical assumptions.
- Carvedilol should be considered a valuable therapeutic option for managing CHF.
Objective:
Carvedilol, a beta-adrenoceptor blocking agent with additional alpha(1)-adrenoceptor blocking properties, has been shown to improve left ventricular function in chronic heart failure (CHF). However, its effect on mortality has recently been the subject of controversial discussion. The aim of this meta-analysis is to review the data on mortality from two large study programs (the US Carvedilol Heart Failure Study and the study by the Australia/New Zealand Heart Failure Research Collaborative Group) on additional carvedilol treatment in CHF standard therapy and to analyse the design and limitations of the individual studies.
Methods And Results:
For determination of overall, mortality, all patients who died and all patients who were withdrawn for other reasons during the open run-in phase of the studies were assigned to the carvedilol group to create a "worst-case analysis." Meta-analysis of mortality data using the random effects model shows a significantly reduced relative risk of 0.55 x 95%-confidence interval 0.325-0.924; p < 0.05 of death in patients treated with carvedilol compared with patient on standard treatment only.
Conclusion:
Treatment of CHF using carvedilol significantly reduces mortality in patients with CHF, even if the "worst case" is assumed by assigning all deaths in the open run-in phase to carvedilol.